Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia

Shock

Volumn 29, Issue 4, 2008, Pages 475-482

  Mayr, Florian B ^a   Firbas, Christa ^a   Leitner, Judith M ^a   Spiel, Alexander O ^a   Reiter, Rosemarie A ^a   Beyer, Diana ^b   Meyer, Michael ^b   Wolff, Gerhard ^b   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Revotar Biopharmaceuticals AG   (Germany)

Author keywords

Inflammation; Leukocytes; Real time polymerase chain reaction; Selectins; Tissue factor

Indexed keywords

BIMOSIAMOSE; INTERLEUKIN 6; PLACEBO; SELECTIN; TUMOR NECROSIS FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL POPULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; ENDOTOXEMIA; HEMODYNAMICS; HUMAN; LEUKOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD PLATELETS; CELL ADHESION MOLECULES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTOXEMIA; FLOW CYTOMETRY; HEMODYNAMICS; HEXANES; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MANNOSE; PLATELET MEMBRANE GLYCOPROTEIN IIB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELECTINS; THROMBOPLASTIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40949086098     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318142c4e8     Document Type: Article

References (54)

1. Kansas GS: Selectins and their ligands: current concepts and controversies. Blood 88:3259-3287, 1996.
2. Dong ZM, Wagner DD: Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 132:369-375, 1998.
3. Roldan V, Marin F, Lip GY, Blann AD: Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 90:1007-1020, 2003.
4. Blann AD, Nadar SK, Lip GY: The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24:2166-2179, 2003.
5. Verhaar MC, Beutler JJ, Gaillard CA, Koomans HA, Fijnheer R, Rabelink TJ: Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens 16:45-50, 1998.
6. Cambien B, Wagner DD: A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 10:179-186, 2004.
7. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD: Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 97:13835-13840, 2000.
8. Yang J, Furie BC, Furie B: The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 81:1-7, 1999.
9. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B: P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 91:8767-8771, 1994.
10. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197:1585-1598, 2003.
11. Sullivan VV, Hawley AE, Farris DM, Knipp BS, Varga AJ, Wrobleski SK, Thanapron P, Eagleton MJ, Myers DD, Fowlkes JB, et al.: Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res 109:1-7, 2003.
12. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW: P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 38:1075-1089, 2003.
13. Herrmann SM, Ricard S, Nicaud V, Mallet C, Evans A, Ruidavets JB, Arveiler D, Luc G, Cambien F: The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet 7:1277-1284, 1998.
14. Jilma B, Marsik C, Kovar F, Wagner OF, Jilma-Stohlawetz P, Endler G: The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia. Blood 105:2380-2383, 2005.
15. Santos AA, Wilmore DW: The systemic inflammatory response: perspective of human endotoxemia. Shock 6(Suppl 1):S50-S56, 1996.
16. Mayr FB, Jilma B: Coagulation interventions in experimental human endotoxemia. Transl Res 148:263-271, 2006.
17. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF: Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159:857-863, 1999.
18. Derhaschnig U, Pachinger C, Jilma B: Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J 147:E17, 2004.
19. Stohlawetz P, Folman CC, Von dem Borne AE, Pernerstorfer T, Eichler HG, Panzer S, Jilma B: Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 81:613-617, 1999.
20. Marsik C, Halama T, Cardona F, Wlassits W, Mayr F, Pleiner J, Jilma B: Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 20:493-496, 2003.
21. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21:222-229, 2004.
22. Graninger M, Marsik C, Dukic T, Wagner OF, Blann AD, Jilma B: Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock 19:448-451, 2003.
23. Kovar FM, Marsik C, Cvitko T, Wagner OF, Jilma B, Endler G: The tumor necrosis factor alpha-308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 27:238-241, 2007.
24. Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B: Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 79:23-34, 2006.
25. Leitner JM, Jilma B, Mayr FB, Cardona F, Spiel AO, Firbas C, Rathgen K, Stähle H, Schühly U, Graefe-Mody EU: Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin induced coagulation. Clin Pharmacol Ther 81:858-866, 2007.
26. Lowry SF: Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 24:94-100, 2005.
27. Kogan TP, Dupre B, Bui H, McAbee KL, Kassir JM, Scott IL, Hu X, Vanderslice P, Beck PJ, Dixon RA: Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)- 4-(2-a-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J Med Chem 41:1099-1111, 1998.
28. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS: Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 105:769-775, 2000.
29. Palma-Vargas JM, Toledo-Pereyra L, Dean RE, Harkema JM, Dixon RA, Kogan TP: Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg 185:365-372, 1997.
30. Abraham WM, Ahmed A, Sabater JR, Lauredo IT, Botvinnikova Y, Bjercke RJ, Hu X, Revelle BM, Kogan TP, Scott IL, et al.: Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 159:1205-1214, 1999.
31. Anaya-Prado R, Ramos-Kelly JR, Toledo-Pereyra LH, Walsh J, Ward PA: Multiple selectin blockade with a small-molecule selectin inhibitor does not affect survival after a second inflammatory challenge with nonlethal LPS. J Invest Surg 15:171-180, 2002.
32. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, Wolff G: Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 19:233-241, 2006.
33. Friedrich M, Bock D, Philipp S, Ludwig N, Sabat R, Wolk K, Schroeter-Maas S, Aydt E, Kang S, Dam TN, et al.: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 297:345-351, 2006.
34. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B: Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102:2093-2098, 2003.
35. T method. Methods 25:402-408, 2001.
36. Jilma B: Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138:152-163, 2001.
37. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B: Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111:1250-1252, 2000.
38. Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B: Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 4:411-416, 2006.
39. Reiter R, Derhaschnig U, Spiel AO, Keen P, Cardona F, Mayr F, Jilma B: Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 90:898-903, 2003.
40. Meyer M, Jilma B, Zahlten R, Wolff G: Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. Int J Clin Pharmacol Ther 43:463-471, 2005.
41. Stolley PD, Strom BL: Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 39:489-490, 1986.
42. Mayr FB, Spiel A, Leitner J, Marsik C, Germann P, Ullrich R, Wagner O, Jilma B: Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med 171:354-360, 2005.
43. Jilma-Stohlawetz P, Folman CC, Von dem Borne AE, Pernerstorfer T, Hollenstein U, Knechtelsdorfer M, Eichler HG, Jilma B: Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med 137:64-69, 2001.
44. Andre P: P-selectin in haemostasis. Br J Haematol 126:298-306, 2004.
45. Polgar J, Matuskova J, Wagner DD: The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 3:1590-1596, 2005.
46. Vandendries ER, Furie BC, Furie B: Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 92:459-466, 2004.
47. Clinical Trial Report R003. Efficacy, tolerability and pharmacokinetics of bimosiamose disodium (TBC1269Z) in patients with moderate to severe psoriasis after one-daily intralesional injection of TBC1269Z given over a period of 14 days, Hennigsdorf, 2002.
48. Lindmark E, Tenno T, Siegbahn A: Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 20:2322-2328, 2000.
49. Schoenmakers SH, Versteeg HH, Groot AP, Reitsma PH, Spek CA: Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J Thromb Haemost 2:2185-2193, 2004.
50. Van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, Buurman WA, Hack CE, Ten Cate JW, Agosti JM, et al.: Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 89:3727-3734, 1997.
51. Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B: Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 32:1136-1140, 2004.
52. Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Brown SL, et al.: Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 25:816-827; discussion 828, 1997.
53. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW: P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med 179:329-334, 1994.
54. Hollenstein U, Homoncik M, Stohlawetz PJ, Marsik C, Sieder A, Eichler HG, Jilma B: Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis 182:343-346, 2000.